ALK and neoplasm: In further analyses, we divided patients into three groups according to their concomitant mutations: patients with ALK-rearrangement only (n = 81), patients with ALK rearrangement and concomitant tumor-suppressor gene mutations (n = 35), and patients with ALK rearrangement and concomitant oncogene mutations irrespective of tumor-suppressor gene mutations (n = 16).